RA Capital Preps New Biotech SPAC — With an Eye on China’s Risks

The firm’s third blank check company aims to tap rising pharma demand for external innovation while warning investors about the regulatory uncertainty of China deals.

Stephen Taub March 27, 2026

RA Capital Management has filed to raise $50 million for its latest biotechnology‑focused SPAC, Research Alliance Corp. III, according to a recent regulatory filing. The special purpose acquisition company is led by RA Capital partner Matthew Hammond, with analyst Henry Stusnick.The SPAC stated in the

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.18.00 build:2026-03-26 Login